Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dipyridamole specifically decreases platelet-derived growth factor release from platelets.

K Takehara1, A Igarashi, Y Ishibashi

  • 1Department of Dermatology, University of Tokyo Branch Hospital, Japan.

Pharmacology
|January 1, 1990
PubMed
Summary

Dipyridamole uniquely reduces platelet-derived growth factor (PDGF) levels during blood clotting, unlike other anti-platelet drugs. This selective action suggests dipyridamole could prevent disorders linked to PDGF.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence, risk factors, and clinical implications of enfortumab vedotin-related cutaneous toxicity in urothelial carcinoma: a large-scale, real-world study in Japan.

ESMO real world data and digital oncology·2026
Same author

The impact of omalizumab on paid and unpaid work productivity among severe Japanese cedar pollinosis (JCP) patients.

Journal of medical economics·2022
Same author

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).

The British journal of dermatology·2021
Same author

Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials.

The British journal of dermatology·2019
Same author

Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.

The British journal of dermatology·2019
Same author

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.

The British journal of dermatology·2019

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • Platelet-derived growth factor (PDGF) plays a role in various disorders.
  • Previous research indicated dipyridamole reduces serum PDGF levels by inhibiting release during blood clotting.

Purpose of the Study:

  • To investigate the specificity of dipyridamole's effect on PDGF levels.
  • To determine if dipyridamole selectively reduces PDGF compared to other platelet factors.

Main Methods:

  • Comparison of dipyridamole with other anti-platelet agents (aspirin, trapidil, ticlopidine).
  • Measurement of PDGF levels in human serum after blood clotting.
  • Analysis of other alpha-granule factors (beta-thromboglobulin, platelet factor IV).

Main Results:

Related Experiment Videos

  • Dipyridamole specifically decreased PDGF levels.
  • Aspirin, trapidil, and ticlopidine did not show this effect.
  • Dipyridamole selectively reduced PDGF without affecting beta-thromboglobulin or platelet factor IV.

Conclusions:

  • Dipyridamole's effect on reducing PDGF is specific among tested anti-platelet drugs.
  • The selective reduction of PDGF suggests therapeutic potential for dipyridamole.
  • Dipyridamole may be a valuable agent for preventing PDGF-related pathological conditions.